Medpace Holdings, Inc. $MEDP Shares Acquired by CWA Asset Management Group LLC

CWA Asset Management Group LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 119.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,827 shares of the company’s stock after purchasing an additional 1,536 shares during the quarter. CWA Asset Management Group LLC’s holdings in Medpace were worth $1,588,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Norges Bank acquired a new position in shares of Medpace in the second quarter valued at approximately $66,597,000. Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after buying an additional 211,411 shares during the last quarter. Clarkston Capital Partners LLC purchased a new position in shares of Medpace during the second quarter valued at approximately $40,569,000. Finally, Bares Capital Management Inc. lifted its stake in shares of Medpace by 319.2% during the second quarter. Bares Capital Management Inc. now owns 157,084 shares of the company’s stock valued at $49,302,000 after buying an additional 119,608 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Down 1.8%

Shares of MEDP opened at $452.51 on Monday. The firm has a market cap of $12.84 billion, a PE ratio of 29.58, a price-to-earnings-growth ratio of 2.17 and a beta of 1.44. The company’s fifty day moving average is $509.09 and its two-hundred day moving average is $538.69. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue for the quarter was up 32.0% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Royal Bank Of Canada initiated coverage on shares of Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price for the company. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.